This company has been marked as potentially delisted and may not be actively trading. NASDAQ:AGRX Agile Therapeutics (AGRX) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisCompetitorsTrendsBuy This Stock About Agile Therapeutics Stock (NASDAQ:AGRX) Get Agile Therapeutics alerts:Sign Up Key Stats Today's Range$1.51▼$1.5150-Day Range$1.43▼$1.5152-Week Range$0.20▼$2.63VolumeN/AAverage Volume352,864 shsMarket Capitalization$10.35 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Agile Therapeutics, Inc., a women's healthcare company, engages in the research, development, and commercialization of prescription contraceptive products for women in the United States. It offers Twirla, a once-weekly prescription combination hormonal contraceptive patch. The company is also developing a pipeline of Twirla line extensions and other products, including AG200-15 Extended Regimen (ER), a regimen that allows a woman to have four episodes of withdrawal bleeding per year; AG200-15 smaller patch (SmP), which is a regimen designed to provide shorter and lighter withdrawal bleeds, and enhance contraceptive efficacy; AG200-15 ER SmP, a regimen to allow a woman to extend the length of her contraceptive cycle, as well as have shorter and lighter withdrawal bleeding episodes per year; and P-Patch, a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen. Agile Therapeutics, Inc. was incorporated in 1997 and is headquartered in Princeton, New Jersey. Read More Receive AGRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Agile Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. AGRX Stock News HeadlinesAgile Therapeutics, Inc.: Agile Therapeutics Inc. Announces Completion of Acquisition by Insud Pharma, S.L.August 27, 2024 | finanznachrichten.deAgile Therapeutics Inc. Announces Completion of Acquisition by Insud Pharma, S.L.August 26, 2024 | globenewswire.comYour book attachedYour Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners guide...please take a few seconds and download it right now before your download link expires. That way, no matter what it costs in the future, you'll have a free copy on your computer.May 5 at 1:00 AM | Profits Run (Ad)Agile Leadership for Pharma and Biopharma Professionals in a Hybrid World: 2-Day Training Course (Online) November 18-19, 2024 - Become Competent and Familiar in a Range of Well-Recognised Leadership TechniquesAugust 7, 2024 | globenewswire.comSTOCKHOLDER INVESTIGATION: The M&A Class Action Firm Investigates Merger of Agile Therapeutics, Inc. - AGRXJuly 3, 2024 | prnewswire.comAGRX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Agile Therapeutics, Inc. Is Fair to ShareholdersJune 26, 2024 | businesswire.comAgile Therapeutics Inc. Announces Definitive Merger Agreement with Insud Pharma, S.L.June 26, 2024 | globenewswire.comAgile Therapeutics, Inc.: Agile Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate UpdateMay 16, 2024 | finanznachrichten.deSee More Headlines AGRX Stock Analysis - Frequently Asked Questions How were Agile Therapeutics' earnings last quarter? Agile Therapeutics, Inc. (NASDAQ:AGRX) released its earnings results on Tuesday, November, 2nd. The specialty pharmaceutical company reported ($7.20) earnings per share for the quarter, topping analysts' consensus estimates of ($7.60) by $0.40. The specialty pharmaceutical company had revenue of $1.29 million for the quarter, compared to the consensus estimate of $1.49 million. Read the conference call transcript. When did Agile Therapeutics' stock split? Agile Therapeutics shares reverse split before market open on Wednesday, April 27th 2022.The 1-40 reverse split was announced on Wednesday, April 27th 2022. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, April 27th 2022. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. When did Agile Therapeutics IPO? Agile Therapeutics (AGRX) raised $55 million in an IPO on Thursday, May 22nd 2014. The company issued 9,166,667 shares at $6.00 per share. What other stocks do shareholders of Agile Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Agile Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), CrowdStrike (CRWD) and Arista Networks (ANET). Company Calendar Last Earnings11/02/2021Today5/05/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:AGRX CIK1261249 Webwww.agiletherapeutics.com Phone(609) 683-1880FaxN/AEmployees30Year Founded1997Profitability EPS (Trailing Twelve Months)($3.65) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$14.47 million Net Margins-36.24% Pretax Margin-36.24% Return on EquityN/A Return on Assets-147.37% Debt Debt-to-Equity RatioN/A Current Ratio0.56 Quick Ratio0.38 Sales & Book Value Annual Sales$19.98 million Price / Sales0.52 Cash FlowN/A Price / Cash FlowN/A Book Value($5.51) per share Price / Book-0.27Miscellaneous Outstanding Shares6,856,000Free Float6,822,000Market Cap$10.35 million OptionableNot Optionable Beta1.58 Social Links (Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free Report This page (NASDAQ:AGRX) was last updated on 5/5/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | SponsoredIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...American Alternative | SponsoredYour book attachedYour Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...Profits Run | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredSell 99% of Your Stocks, Do THIS Instead…Millionaire Trader Exposes: "The Single Stock Income Plan" With over 6,000 stocks on the market to choose ...The Oxford Club | SponsoredTrade this between 9:30 and 10:45 am ESTThe first 75 minutes of the trading day may be the most overlooked window for consistent opportunities.If you ...Base Camp Trading | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | SponsoredElon Unveils AI Passive Income Stream for Millions of AmericansDuring Tesla's last earnings call, Elon Musk outlined a new AI-driven approach he says could generate $30,000-...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Agile Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Agile Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.